Keywords
How to Cite
Abstract
Ovarian cancer (OC) is the most aggressive among the neoplasms of the female reproductive sphere, the survival rate for OC remains low and varies between countries. The aim of the study was to evaluate the predictors of OC survival in the Arkhangelsk region (AR) over the period 2000-2021 by data of the regional population-based cancer registry. Another objective was to assess the trends of the OC survival during the COVID-19 pandemic.
Materials and methods. Total data on OC for the period 2000-2021 were obtained from the Arkhangelsk Regional Cancer Registry (ARCR). Cancer-specific survival (CSS) was calculated using Life tables and Kaplan-Meier methods. The degree of influence of prognostic factors on CSS was assessed using Cox regression model of proportional risks.
Results. 2703 cases were analyzed. The one-year and 5-year survival of OSV for the entire population was 70.4% (95% confidence interval (CI) 68.6% - 72.1%) and 51.4% (95% CI 49.3% - 53.4%). The 5-year survival rate was 93.1% (95% CI 90,9% – 94,8%), 74,7% (95% CI 69,4% – 79,3%), 29,1% (95% CI 25,7% – 32,6%), 9,4% (95% CI 6,7% – 12.6%) at stages I, II, III, IV, respectively. The significant factors of the unfavorable prognosis were elderly age (the hazard ratios (HR) compared to the subgroup under 39 years 3.6-13.9), rural inhabitance (HR 1.3), uncertain morphology of RS (HR 3.6) and lack of information about cancer-directed treatment (HR 5.8). In the multivariate model, age, stage, and availability of information about treatment had an independent influence on the prognosis. The one-year survival rate during the COVID–19 pandemic was 71.8% (95% CI 65.1% - 77.4%), in 2013-2019 – 73.8% (95% CI 70.9% - 76.5%). Adjusted risk of death for the period 2020-2021 has not changed, compared with the previous period.
Conclusion. In the epidemiological analysis was found that an adverse effect on the outcome of the disease is caused by older age and living in areas remote from the city, which can be partially explained by the higher stage at diagnosis and less often used cancer-directed treatment in these categories of patients. The survival rate of patients during the COVID-19 pandemic did not significantly decrease. A high-resolution study is planned for a more detailed analysis.
References
Global Cancer Observatory: Cancer Today [Internet]. Lyon, France: International Agency for Research on Cancer [accessed on 26.11.2022]. Available from: https://gco.iarc.fr/today.
Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022:239 [Kaprin AD, Starinsky VV, Shakhzadova AO. The state of oncological care for the population of Russia in 2021. Ed. by AD Kaprina, VV Starinsky, AO Shakhzadova. M.: MSROI P.A. Gertsen, FSBI «NMRC of Radiology» MH of Russia. 2022;239 (In Russ.)].
Ginsburg O, Bray F, Coleman MP, et al. The global burden of women's cancers: a grand challenge in global health. Lancet. 2017;389(10071):847860. doi:10.1016/S0140-6736(16)31392-7.
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):10231075. doi:10.1016/S0140-6736(17)33326-3.
Swiecki-Sikora AL, Craig AD, Chu CS. Financial toxicity in ovarian cancer. Int J Gynecol Cancer. 2022;32(11):1450–4. doi:10.1136/ijgc-2022-003594.
Trétarre B, Molinié F, Woronoff AS, et al. Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012. Gynecol Oncol. 2015;139(2):3249. doi:10.1016/j.ygyno.2015.09.013.
Вальков М.Ю., Карпунов А.А., Коулман М.П., и др. Популяционный раковый регистр как ресурс для науки и практического здравоохранения. Экология человека. 2017;24(5):5462 [Valkov MY, Karpunov AA, Coleman MP, et al. The population-based cancer registry as a resource for research and practical healthcare. Ekologiya cheloveka (Human Ecology). 2017;24(5):54–62 (In Russ.)]. doi:10.33396/1728-0869-2017-5-54-62.
Мерабишвили В.М., Дятченко О.Т. Противораковая борьба в деятельности НИИ онкологии им. проф. Н.Н. Петрова. Вопросы онкологии. 2007;53(3):355365 [Merabishvili VM, Diatchenko OТ. Anti-cancer struggle in the activity of N.N. Petrov Research Institute of Oncology. Voprosy Onkologii. 2007;53(3):35565 (In Russ.)].
Barchuk A, Tursun-Zade R, Belayev A, et al. Comparability and validity of cancer registry data in the northwest of Russia. Acta Oncol. 2021;60(10):1264-71. doi:10.1080/0284186X.2021.1967443.
Yang L, Yu J, Zhang S, et al. A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis. J Ovarian Res. 2022;15(1):26. doi:10.1186/s13048-022-00958-6.
Hamidou Z, Causeret S, Dabakuyo TS, et al. Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years. BMC Cancer. 2010;10:622. doi:10.1186/1471-2407-10-622.
Akeson M, Jakobsen AM, Zetterqvist BM, et al. A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer. 2009;19(1):11623. doi:10.1111/IGC.0b013e3181991b13.
Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):92836. doi:10.1016/S1470-2045(15)00086-8.
Guan LY, Lu Y. New developments in molecular targeted therapy of ovarian cancer. Discov Med. 2018;26(144):219229.
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):13028. doi:10.1200/JCO.2013.51.4489.
Валькова Л.Е., Левит М.Л., Мерабишвили В.М., и др. Первичная эпидемиологическая оценка эффективности диспансеризации отдельных групп взрослого населения в роли скрининга онкологических заболеваний по данным Архангельского областного канцер-регистра. Research'n Practical Medicine Journal. 2019;6(4):187199 [Valkova LE, Levit ML, Merabishvili VM, et al. Primary epidemiological evaluation of the effectiveness of the All-National Dispensarization as a cancer screening by the data of the Arkhangelsk Regional Cancer Registry. Research and Practical Medicine Journal. 2019;6(4):187–99 (In Russ.)]. doi:10.17709/2409-2231-2019-6-4-20.
Валькова Л.Е., Дяченко А.А., Мерабишвили В.М., и др. Влияние пандемии COVID-19 на показатели заболеваемости злокачественными опухолями, подлежащими скринингу в рамках диспансеризации (популяционное исследование). Сибирский онкологический журнал. 2022;21(6):7–16 [Valkova LE, Dyachenko AA, Merabishvili VM, et al. Impact of the СOVID-19 pandemic on cancer incidence in patients undergoing cancer screening during annual health checkup (population-based study). Siberian journal of oncology. 2022;21(6):7–16 (In Russ.)]. doi:10.21294/1814-4861-2022-21-6-7-16.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2023